These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 18444848)

  • 1. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
    Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
    Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
    Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
    Gesser RM; McCarroll K; Teppler H; Woods GL
    J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
    Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
    Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
    Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
    Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
    Wells WG; Woods GL; Jiang Q; Gesser RM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.